Liver-Specific Ionizable Lipid Nanoparticles Mediated Efficient RNA Interference to Clear "Bad Cholesterol"
Chuangjia Huang1,2, Yu Zhang3, Jianfen Su1,2
1Department of Cardiology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, People's Republic of China.
Background:
High-level low-density lipoprotein cholesterol (LDL-C) plays a vital role in the development of atherosclerotic cardiovascular disease. Low-density lipoprotein receptors (LDLRs) are scavengers that bind to LDL-C in the liver. LDLR proteins are regulated by proprotein convertase subtilisin/kexin type 9 (PCSK9), which mediates the degradation of LDLR and adjusts the level of the plasma LDL-C. The low expression of PCSK9 leads to the up-regulation of liver LDLRs and the reduction of plasma LDL-C. Hepatocytes are attractive targets for small interfering RNA (siRNA) delivery to silence Pcsk9 gene, due to their significant role in LDL-C regulation.
Methods:
Here, a type of liver-specific ionizable lipid nanoparticles is developed for efficient siRNA delivery. This type of nanoparticles shows high stability, enabling efficient cargo delivery specifically to hepatocytes, and a membrane-active polymer that reversibly masks activity until an acidic environment is reached.
Results:
Significantly, the siPcsk9 (siRNA targeting to Pcsk9)-loaded nanoparticles (GLP) could silence 90% of the Pcsk9 mRNA in vitro. In vivo study showed that the improved accumulation of GLP in the liver increased LDLR level by 3.35-fold and decreased plasma LDL-C by 35%.
Conclusion:
GLP has shown a powerful effect on reducing LDL-C, thus providing a potential therapy for atherosclerotic cardiovascular disease.
Insights
New liver-targeted nanoparticles effectively deliver siRNA to reduce PCSK9 levels. This approach significantly lowers LDL-C, offering a promising new therapy for atherosclerotic cardiovascular disease.
Area of Science:
- Biotechnology
- Cardiovascular Research
- Gene Therapy
Background:
- High LDL-C is a key factor in atherosclerotic cardiovascular disease.
- PCSK9 protein regulates LDL receptors (LDLRs) and plasma LDL-C levels.
- Reducing PCSK9 expression up-regulates liver LDLRs and lowers LDL-C.
Purpose of the Study:
- To develop liver-specific nanoparticles for efficient siRNA delivery.
- To target hepatocytes for gene silencing of Pcsk9.
- To evaluate the therapeutic potential for lowering LDL-C.
Main Methods:
- Development of liver-specific ionizable lipid nanoparticles (GLP) for siRNA delivery.
- Nanoparticles feature high stability and a membrane-active polymer for targeted release.
- In vitro and in vivo studies to assess gene silencing and LDL-C reduction.
Main Results:
- GLP nanoparticles achieved 90% Pcsk9 mRNA silencing in vitro.
- In vivo studies showed a 3.35-fold increase in liver LDLR levels.
- Plasma LDL-C was reduced by 35% in vivo.
Conclusions:
- GLP nanoparticles demonstrate potent LDL-C lowering effects.
- This technology offers a potential therapeutic strategy for atherosclerotic cardiovascular disease.
- Targeted siRNA delivery to hepatocytes is effective for managing hypercholesterolemia.
More Related Videos
Related Concept Videos
02:15Experimental RNAi
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
02:30Small interfering RNAs (siRNA)